Incyte (INCY) Change in Accured Expenses (2010 - 2026)
Incyte (INCY) posted Change in Accured Expenses of -$84.7 million for Q1 2026, down 161.15% on a QoQ basis from $138.5 million in Q4 2025, and down 213.21% year-over-year from $74.8 million in Q1 2025.
Incyte (INCY) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Incyte's Change in Accured Expenses history runs 17 years deep, the most recent figure standing at -$84.7 million for Q1 2026.
- Quarterly Change in Accured Expenses fell 213.21% year-over-year to -$84.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$307.8 million (down 223.94% YoY) and the FY2025 annual result came in at -$148.2 million, down 153.13% from the prior year.
- Change in Accured Expenses was -$84.7 million for Q1 2026 at Incyte, down from $138.5 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $138.5 million in Q4 2025 and bottomed at -$476.7 million in Q2 2025.
- A 5-year average of $29.2 million and a median of $71.9 million in 2023 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2022 — Change in Accured Expenses surged 2430.46% — and 2025, when it tumbled 510.9%.
- Incyte's Change in Accured Expenses stood at $47.8 million in 2022, then soared by 143.08% to $116.2 million in 2023, then climbed by 11.66% to $129.8 million in 2024, then advanced by 6.76% to $138.5 million in 2025, then plunged by 161.15% to -$84.7 million in 2026.
- Business Quant data shows INCY's Change in Accured Expenses at -$84.7 million in Q1 2026, $138.5 million in Q4 2025, and $115.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 69,146.49 Bn | 69,146.20 Bn | - | 1.13 Mn |
| 2 | Nanobiotix | 1,942.19 Bn | 1,942.13 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | 931,000.00 |
| 4 | BeOne Medicines | 475.42 Bn | 470.63 Bn | 1.35 Bn | -16.82 Mn |
| 5 | Vertex Pharmaceuticals | 123.32 Bn | 116.08 Bn | 2.59 Bn | 23.10 Mn |
| 6 | Regeneron Pharmaceuticals | 69.80 Bn | 61.04 Bn | 3.31 Bn | 107.70 Mn |
| 7 | Belite Bio | 63.28 Bn | 63.28 Bn | - | - |
| 8 | Argenx Se | 56.67 Bn | 51.48 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 38.15 Bn | 38.15 Bn | - | -16.74 Mn |
| 10 | Incyte | 23.92 Bn | 19.90 Bn | 1.17 Bn | -84.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -84.73 Mn |
| Mar 31, 2026 | -84.73 Mn |
| Dec 31, 2025 | 138.55 Mn |
| Dec 31, 2025 | 138.55 Mn |
| Sep 30, 2025 | 115.14 Mn |
| Sep 30, 2025 | 115.14 Mn |
| Jun 30, 2025 | -476.73 Mn |
| Jun 30, 2025 | -476.73 Mn |
| Mar 31, 2025 | 74.84 Mn |
| Mar 31, 2025 | 74.84 Mn |
| Dec 31, 2024 | 129.77 Mn |
| Dec 31, 2024 | 129.77 Mn |
| Sep 30, 2024 | 121.74 Mn |
| Sep 30, 2024 | 121.74 Mn |
| Jun 30, 2024 | -78.04 Mn |
| Jun 30, 2024 | -78.04 Mn |
| Mar 31, 2024 | 105.47 Mn |
| Mar 31, 2024 | 105.47 Mn |
| Dec 31, 2023 | 116.22 Mn |
| Dec 31, 2023 | 116.22 Mn |